Federica De Galitiis

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti et al. · Journal for ImmunoTherapy of Cancer · 2019 · 415 citations · Full text

Medicine, Immunology, Oncology +16

Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients

Pier Francesco Ferrucci, Sara Gandini, A. Battaglia et al. · British Journal of Cancer · 2015 · 261 citations · Full text

Life Sciences, Immunology, Oncology +14

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

Alessio Cortellini, Sebastiano Buti, Daniele Santini et al. · The Oncologist · 2019 · 221 citations · Full text

Life Sciences, Immunology, Oncology +17

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma

Michele Del Vecchio, Lorenza Di Guardo, Paolo A. Ascierto et al. · European Journal of Cancer · 2013 · 157 citations · Full text

Medicine, Oncology, Pharmacology +12

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial

Georgina V. Long, Jason J. Luke, Muhammad A. Khattak et al. · The Lancet Oncology · 2022 · 147 citations

Medicine, Clinical Sciences, Oncology +15